β 2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 6, 2006, Pages 633-645

  Iaccarino, Guido ^a   Izzo, Raffaele ^a   Trimarco, Valentina ^a   Cipolletta, Ersilia ^a   Lanni, Francesca ^a   Sorriento, Daniela ^a   Iovino, Gianni Luigi ^a   Rozza, Francesco ^a   De Luca, Nicola ^a   Priante, Ornella ^a   Di Renzo, Gianfranco ^a   Trimarco, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATRIAL NATRIURETIC FACTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; DIURETIC AGENT; ENALAPRIL; GLUTAMINE; GLYCINE; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SYNAPTOPHYSIN; THREONINE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE INCREASE; EMBRYO; FEMALE; GENE OVEREXPRESSION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; GENETICS; GENOTYPE; HETEROZYGOTE; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; ATENOLOL; ENALAPRIL; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 33845385712     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.09.006     Document Type: Article

References (59)

1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
2. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
3. Frohlich E.D., Apstein C., Chobanian A.V., Devereux R.B., Dustan H.P., Dzau V., et al. The heart in hypertension. N Engl J Med 327 (1992) 998-1008
4. Adams T.D., Yanowitz F.G., Fisher A.G., Ridges J.D., Nelson A.G., Hagan A.D., et al. Heritability of cardiac size: an echocardiographic and electrocardiographic study of monozygotic and dizygotic twins. Circulation 71 (1985) 39-44
5. Harshfield G.A., Grim C.E., Hwang C., Savage D.D., and Anderson S.J. Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins. Am J Hypertens 3 (1990) 538-543
6. Post W.S., Larson M.G., Myers R.H., Galderisi M., and Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 30 (1997) 1025-1028
7. Turner S.T., and Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation 102 Suppl 4 (2000) IV40-IV45
8. Iaccarino G., Barbato E., Cipoletta E., Fiorillo A., and Trimarco B. Role of the sympathetic nervous system in cardiac remodeling in hypertension. Clin Exp Hypertens 23 (2001) 35-43
9. Akhter S.A., Milano C.A., Shotwell K.F., Cho M.C., Rockman H.A., Lefkowitz R.J., et al. Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. J Biol Chem 272 (1997) 21253-21259
10. Engelhardt S., Hein L., Wiesmann F., and Lohse M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96 (1999) 7059-7064
11. Liggett S.B., Tepe N.M., Lorenz J.N., Canning A.M., Jantz T.D., Mitarai S., et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101 (2000) 1707-1714
12. Iaccarino G., Barbato E., Cipolleta E., Esposito A., Fiorillo A., Koch W.J., et al. Cardiac betaARK1 upregulation induced by chronic salt deprivation in rats. Hypertension 38 (2001) 255-260
13. Iaccarino G., Tomhave E.D., Lefkowitz R.J., and Koch W.J. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98 (1998) 1783-1789
14. Bono M., Cases A., Calls J., Gaya J., Jimenez W., Carretero J., et al. Effect of antihypertensive treatment on the increased beta 2-adrenoceptor density in patients with essential hypertension. Am J Hypertens 8 Pt 1 (1995) 487-493
15. Laflamme K.A., Oster L., Cardinal R., and de Champlain J. Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. Hypertension 30 Pt 1 (1997) 278-287
16. Eisenach J.H., Barnes S.A., Pike T.L., Sokolnicki L.A., Masuki S., Dietz N.M., et al. Arg16/Gly beta2-adrenergic receptor polymorphism alters the cardiac output response to isometric exercise. J Appl Physiol 99 (2005) 1776-1781
17. Liggett S.B. Molecular and genetic basis of beta2-adrenergic receptor function. J Allergy Clin Immunol 104 Pt 2 (1999) S42-S46
18. Bengtsson K., Orho-Melander M., Melander O., Lindblad U., Ranstam J., Rastam L., et al. Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension 37 (2001) 1303-1308
19. Bray M.S., and Boerwinkle E. The role of beta(2)-adrenergic receptor variation in human hypertension. Curr Hypertens Rep 2 (2000) 39-43
20. Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., et al. beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33 (1999) 1425-1430
21. Kotanko P., Binder A., Tasker J., DeFreitas P., Kamdar S., Clark A.J., et al. Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. Hypertension 30 (1997) 773-776
22. Tomaszewski M., Brain N.J., Charchar F.J., Wang W.Y., Lacka B., Padmanabahn S., et al. Essential hypertension and beta2-adrenergic receptor gene: linkage and association analysis. Hypertension 40 (2002) 286-291
23. Iaccarino G., Lanni F., Cipolletta E., Trimarco V., Izzo R., Iovino G.L., et al. The Glu27 allele of the beta2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J Hypertens 22 (2004) 2117-2122
24. Bruck H., Leineweber K., Beilfuss A., Weber M., Heusch G., Philipp T., et al. Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation. Clin Pharmacol Ther 74 (2003) 255-263
25. Bruck H., Leineweber K., Park J., Weber M., Heusch G., Philipp T., et al. Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 78 (2005) 232-238
26. Green S.A., Turki J., Bejarano P., Hall I.P., and Liggett S.B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13 (1995) 25-33
27. Dishy V., Sofowora G.G., Xie H.G., Kim R.B., Byrne D.W., Stein C.M., et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345 (2001) 1030-1035
28. Hoffmann C., Leitz M.R., Oberdorf-Maass S., Lohse M.J., and Klotz K.N. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 151-159
29. Bohm M., Grabel C., Knorr A., and Erdmann E. Treatment in hypertensive cardiac hypertrophy, I. Neuropeptide Y and beta-adrenoceptors. Hypertension 25 (1995) 954-961
30. Zechner D., Thuerauf D.J., Hanford D.S., McDonough P.M., and Glembotski C.C. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 139 (1997) 115-127
31. Sugden P.H. Signalling pathways in cardiac myocyte hypertrophy. Ann Med 33 (2001) 611-622
32. McDonald P.H., and Lefkowitz R.J. Beta-Arrestins: new roles in regulating heptahelical receptors' functions. Cell Signal 13 (2001) 683-689
33. De Luca N., Izzo R., Iaccarino G., Malini P.L., Morisco C., Rozza F., et al. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens 23 (2005) 1417-1423
34. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999) 151-183
35. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
36. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (1977) 613-618
37. Large V., Hellstrom L., Reynisdottir S., Lonnqvist F., Eriksson P., Lannfelt L., et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 100 (1997) 3005-3013
38. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
39. Ganau A., Devereux R.B., Roman M.J., de Simone G., Pickering T.G., Saba P.S., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
40. Iaccarino G., Ciccarelli M., Sorriento D., Galasso G., Campanile A., Santulli G., et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 97 (2005) 1182-1189
41. Rockman H.A., Ross R.S., Harris A.N., Knowlton K.U., Steinhelper M.E., Field L.J., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 88 (1991) 8277-8281
42. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., and Sadoshima J. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276 (2001) 28586-28597
43. Xiang F., Sakata Y., Cui L., Youngblood J.M., Nakagami H., Liao J.K., et al. Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol 290 (2006) H1997-H2006
44. Kupari M., Hautanen A., Lankinen L., Koskinen P., Virolainen J., Nikkila H., et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97 (1998) 569-575
45. Tamaki S., Iwai N., Tsujita Y., and Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 33 Pt 2 (1999) 266-270
46. Schunkert H., Hengstenberg C., Holmer S.R., Broeckel U., Luchner A., Muscholl M.W., et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation 99 (1999) 2255-2260
47. Sasaki M., Oki T., Iuchi A., Tabata T., Yamada H., Manabe K., et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 14 (1996) 1403-1408
48. Hernandez D., Lacalzada J., Salido E., Linares J., Barragan A., Lorenzo V., et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 58 (2000) 889-897
49. Kohno M., Yokokawa K., Minami M., Kano H., Yasunari K., Hanehira T., et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 106 (1999) 544-549
50. Stella P., Bigatti G., Tizzoni L., Barlassina C., Lanzani C., Bianchi G., et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 43 (2004) 265-270
51. Littlejohn M.D., Taylor D.R., Miller A.L., and Kennedy M.A. Determination of beta2-adrenergic receptor (ADRB2) haplotypes by a multiplexed polymerase chain reaction assay. Hum Mutat 20 (2002) 479
52. Taylor D.R., Epton M.J., Kennedy M.A., Smith A.D., Iles S., Miller A.L., et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 172 (2005) 700-703
53. Leineweber K., Buscher R., Bruck H., and Brodde O.E. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 1-22
54. Arnett D.K., de las Fuentes L., and Broeckel U. Genes for left ventricular hypertrophy. Curr Hypertens Rep 6 (2004) 36-41
55. Fagard R., Staessen J., Thijs L., and Amery A. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A metaanalysis of comparative studies. Am J Hypertens 8 Pt 1 (1995) 533-540
56. Wadworth A.N., Murdoch D., and Brogden R.N. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42 (1991) 468-510
57. Sakata K., Shirotani M., Yoshida H., and Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 32 (1998) 438-443
58. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
59. Trimarco B., Ricciardelli B., De Luca N., De Simone A., Cuocolo A., Galva M.D., et al. Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents. Circulation 72 (1985) 38-46